| Subject: | Anti-Inflammatory Drug Vioxx (Rofecoxib) Removed from Market |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 4 Oct 2004 - 10:00 am |
| The FDA has issued a Public Health Advisory about the withdrawal of the anti-inflammatory drug Vioxx (rofecoxib) from the market by the manufacturer, Merck & Co., Inc. Vioxx is a COX-2, NSAID widely used for the treatment of osteoarthritis, rheumatoid arthritis and in some instances menstrual pain. Vioxx is being withdrawn due to results study results which indicated patients taking this drug were at greater risk of cardiovascular events, including heart attack and stroke, particularly if the... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
Related MCN Products:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
